Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01167244 |
Recruitment Status :
Completed
First Posted : July 22, 2010
Last Update Posted : October 12, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma | Drug: BMS-690514 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 11 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase 2 Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response |
Study Start Date : | August 2010 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | April 2011 |

Arm | Intervention/treatment |
---|---|
Experimental: BMS-690514 |
Drug: BMS-690514
Tablets, Oral, 200 mg, once daily, until disease progression or toxicity |
- To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response [ Time Frame: Tumor assessment Day 29 and every 8 weeks from Day 1 thereafter until disease progression ]
- To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response [ Time Frame: Tumor assesments on Day 29 by CT or MRI ]
- To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response [ Time Frame: Tumor assessments every 8 weeks from Day 1 by CT or MRI ]
- To estimate disease control rate and progression free survival in all treated subjects [ Time Frame: Tumor assessment Day 29 and every 8 weeks from Day 1 thereafter until disease progression ]
- To estimate disease control rate and progression free survival in all treated subjects [ Time Frame: Tumor assessment from Day 29 ]
- To estimate disease control rate and progression free survival in all treated subjects [ Time Frame: Tumor assessment every 8 weeks from Day 1 until disease progression ]
- To evaluate safety and tolerability of BMS-690514 in all treated subjects [ Time Frame: Average about 10 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Recurrent, metastatic or progressive NSCLC without any indication of radiotherapy. Subjects must have:
- Pathologically confirmed NSCLC
- Previously received treatment with single agent Gefitinib or Erlotinib and completed treatment at least 2 weeks prior to study entry
- Any one of the following:
- A tumor that harbors an EGFR mutation
- Objective clinical benefit from treatment with Gefitinib or Erlotinib as defined by either documented and confirmed partial or complete response (RECIST or WHO), or significant and durable (≥ 6 months) clinical benefit (stable disease as defined by RECIST or WHO) Progression of NSCLC while on continuous treatment with gefitinib or erlotinib as noted by CT/MRI increase in disease after having a confirmed partial or complete response or evidence of ≥ 6 months of SD within 3 months of study enrollment
Exclusion Criteria:
- Symptomatic brain metastasis
- History of TIA, CVA, or thrombotic/thromboembolic event (within last 6 months)
- History of hemoptysis greater than 10 mL/day within last 30 days
- Uncontrolled or significant cardiovascular disease
- History of uncontrolled diarrhea, Crohn's disease or ulcerative colitis
- Inability to swallow tablets, untreated malabsorption or GI surgery that results in inability to absorb protocol therapy
- Women unwilling to avoid pregnancy or use adequate contraception
- History of allergy or adverse drug reaction to gefitinib or erlotinib

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01167244
Japan | |
Local Institution | |
Kashiwa-Shi, Chiba, Japan, 2778577 | |
Local Institution | |
Osaka-Sayama-Shi, Osaka, Japan, 5898511 | |
Local Institution | |
Sunto-Gun, Shizuoka, Japan, 4118777 | |
Local Institution | |
Koto-Ku, Tokyo, Japan, 1358550 |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Responsible Party: | Study Director, Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT01167244 |
Other Study ID Numbers: |
CA187-020 |
First Posted: | July 22, 2010 Key Record Dates |
Last Update Posted: | October 12, 2015 |
Last Verified: | September 2015 |
Carcinoma, Non-Small-Cell Lung Carcinoma, Bronchogenic Bronchial Neoplasms Lung Neoplasms Respiratory Tract Neoplasms |
Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |